🇺🇸 FDA
Pipeline program

Durvalumab

D9100C00001

Phase 3 mab completed

Quick answer

Durvalumab for Locally Advanced Cervical Cancer is a Phase 3 program (mab) at AstraZeneca with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca
Indication
Locally Advanced Cervical Cancer
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials